James Hickman, Chief Scientist at Hesperos, presents a live webinar on “Multi-Organ Human-on-a-Chip Systems for Predicting Drug Efficacy and Toxicity.”
Learn how advanced human-relevant models are improving the prediction of drug efficacy and safety in preclinical development.
Hesperos’ Human-on-a-Chip® technology earns recognition in a Nature Lab Animal article highlighting advancements in human-relevant, new alternative methods (NAMs) models and publishes new research advancing its sarcopenia-on-a-chip system.
Ask Me Anything: Body-On-A-Chip Michael Shuler, PhD was featured on Technology Network’s Ask Me Anything: Body-On-A-Chip webinar and answered questions from a live audience. January 31, 2025: Hosted by Technology Networks, Hesperos President Michael Shuler, PhD, … Read More
Hesperos Appoints L. Florin as CEO “I am excited to join Hesperos during this period of explosive growth […and] lead this exceptional team as we continue delivering breakthrough solutions that advance drug discovery and benefit patients … Read More
The NIH has awarded Hesperos Inc. a $2 million dollar research grant to develop an advanced, animal free platform to test the potency of Botulinum Toxin (BoT).
Development of an Overdose Model doi.org/10.1038/s41598-023-35694-4 Press Release Link to Publication This research provides an accurate way to model overdose in the lab, using human brain cells programmed to respond to many different opioids. Amid an … Read More
Development of a Malaria-on-a-Chip Model doi.org/10.1038/s41598-023-35694-4 Model developed to study Malaria and potential therapeutics Press Release Link to Publication Hesperos scientists have published a groundbreaking study in Scientific Reports, a Nature journal. The publication, titled “Development … Read More
Hesperos Chief Scientist quoted in the Nature Medicine article discussing the state of the field, including rapid advancement with the adoption of the FDA Modernization Act 2.0.
The FDA Modernization Act 2.0 was signed into law eliminating the animal testing mandate in drug discovery.
In a recent study published in Biomaterials, a team of researchers led by Hesperos Chief Scientist Dr. J. Hickman established a significant finding to better understand ALS etiology and potential new treatment targets.